Ontology highlight
ABSTRACT:
SUBMITTER: Hatzimichael E
PROVIDER: S-EPMC4145824 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
Hatzimichael Eleftheria E Tsolas Evangelos E Briasoulis Evangelos E
Journal of blood medicine 20140819
Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and FMS-related tyrosine kinase 3 providing potential in the treatment of hematological malignancies such as myeloproliferative neoplasias, acute myeloid leukemia, and various lymphomas. Pacritinib has potent antiproliferative activity in Janus kinase 2 and/or FMS-related tyrosine kinase 3 activity-dependent cell lines and an ability to promote apoptosis and inhibit the signal transducers and activato ...[more]